Literature DB >> 27282329

Optimizing the Management of Disabling Spasticity Following Spinal Cord Damage: The Ability Network-An International Initiative.

Anthony Scott Burns1, Indira Lanig2, Klemen Grabljevec3, Peter Wayne New4, Djamel Bensmail5, Per Ertzgaard6, Anand Vishwanath Nene7.   

Abstract

Optimizing the treatment of disabling spasticity in persons with spinal cord damage is hampered by a lack of consensus regarding the use of acceptable definitions of spasticity and disabling spasticity, and the relative absence of decision tools such as clinical guidelines and concise algorithms to support decision-making within the broader clinical community. Many people with spinal cord damage are managed outside specialist centers, and variations in practice result in unequal access to best practice despite equal need. In order to address these issues, the Ability Network-an international panel of clinical experts-was initiated to develop management algorithms to guide and standardize the assessment, treatment, and evaluation of outcomes of persons with spinal cord damage and disabling spasticity. To achieve this, consensus was sought on common definitions through facilitated, in-person meetings. To guide patient selection, an in-depth review of the available tools was performed and expert consensus sought to develop an appropriate instrument. Literature reviews are guiding the selection and development of tools to evaluate treatment outcomes (body functions, activity, participation, quality of life) as perceived by people with spinal cord damage and disabling spasticity, and their caregivers and clinicians. Using this approach, the Ability Network aims to facilitate treatment decisions that take into account the following: the impact of disabling spasticity on health status, patient preferences, treatment goals, tolerance for adverse events, and in cases of totally dependent persons, caregiver burden. Copyright Â
© 2016 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disability evaluation; Guideline; Muscle spasticity; Rehabilitation; Spinal cord diseases; Spinal cord injuries

Mesh:

Year:  2016        PMID: 27282329     DOI: 10.1016/j.apmr.2016.04.025

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  7 in total

1.  Reliability of the Modified Ashworth Scale and Modified Tardieu Scale in patients with spinal cord injuries.

Authors:  P Akpinar; A Atici; F U Ozkan; I Aktas; D G Kulcu; A Sarı; B Durmus
Journal:  Spinal Cord       Date:  2017-05-09       Impact factor: 2.772

2.  A Primary Care Provider's Guide to Spasticity Management in Spinal Cord Injury.

Authors:  Philippines Cabahug; Charles Pickard; Travis Edmiston; Jesse A Lieberman
Journal:  Top Spinal Cord Inj Rehabil       Date:  2020

3.  Intrathecal Baclofen Dosage for Long-Term Treatment of Patients With Spasticity Due to Traumatic Spinal Cord Injuries or Multiple Sclerosis.

Authors:  Bengt Skoog; Björn Hedman
Journal:  Ann Rehabil Med       Date:  2019-10-31

Review 4.  A review and evaluation of patient-reported outcome measures for spasticity in persons with spinal cord damage: Recommendations from the Ability Network - an international initiative.

Authors:  Per Ertzgaard; Anand Nene; Carlotte Kiekens; Anthony S Burns
Journal:  J Spinal Cord Med       Date:  2019-02-13       Impact factor: 1.985

5.  Prevalence and Risk Factors for Spasticity After Stroke: A Systematic Review and Meta-Analysis.

Authors:  Huangling Zeng; Jian Chen; Yang Guo; Sheng Tan
Journal:  Front Neurol       Date:  2021-01-20       Impact factor: 4.003

Review 6.  Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury.

Authors:  Ramiro Palazón-García; Ana María Benavente-Valdepeñas
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

7.  European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.

Authors:  Bo Biering-Soerensen; Valerie Stevenson; Djamel Bensmail; Klemen Grabljevec; Mercedes Martínez Moreno; Elke Pucks-Faes; Joerg Wissel; Mauro Zampolini
Journal:  J Rehabil Med       Date:  2022-01-03       Impact factor: 2.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.